Immune Therapeutics, Inc. appointed Kelly Wilson as new CEO

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Appointment of Kelly Wilson as Chief Executive Officer


On April 12, 2023, the Board of Directors of the Company (the "Board") appointed Kelly O. Wilson, the Company's current Chief Operating Officer, Interim President, and Interim Chief Executive Officer, as the Company's Chief Executive Officer. Ms. Wilson's appointment was effective as of April 12, 2023. Ms. Wilson is elected until her successor is duly elected and qualified.


Ms. Wilson, age 52, has served as the Chief Operating Officer of the Company since August 2022 and as Interim President and Interim Chief Executive Officer since November 3, 2023. From 2013 to April 2020, Ms. Wilson was the Company's Chief Technology Officer. From September 2014 to April 2020, Ms. Wilson also served as the Chief Technology and Information Officer of Cytocom Inc., a clinical-stage biopharmaceutical company and former subsidiary of the Company. From August 2016 to August 2019, Ms. Wilson was the Director of Program and Project Management of Cytocom from April 2020-April 2022; during that time Cytocom merged with Cleveland Biolabs Inc. and became Statera Biopharma Inc. (Nasdaq: STAB). From May 2022 to July 2022, Ms. Wilson was the Chief Operating Officer of Biostax, Inc., an immunotherapy startup. Ms. Wilson graduated with honors from the University of Central Florida with a master's degree in systems design and a bachelor's degree in English.


3


As compensation for services to be rendered to the Company by Ms. Wilson in her official capacity as Chief Executive Officer, the Board approved Amendment No. 1 to the Wilson Consulting Agreement. The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.


There are no arrangements or understandings between Ms. Wilson and any other persons pursuant to which she was selected as Chief Executive Officer. Ms. Wilson is married to Robert Wilson, President, and a director of the Company. Ms. Wilson is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K.


Appointment of Robert Wilson as President 


On April 12, 2023, the Board appointed Robert Wilson, a director of the Company, as President of the Company. Mr. Wilson's appointment was effective as of April 12, 2023. Mr. Wilson was elected until his successor is duly elected and qualified.


Mr. Wilson joined the Board on May 2022. Since June 2022, Mr. Wilson has been a director and the Executive Vice President of Strategy and Planning for Biostax, Inc., an immunotherapy startup. Biostax, Inc. is a Delaware corporation that has no direct or indirect ownership interest in and is not directly or indirectly owned by the Company. Since December 2020, Mr. Wilson has been a director and the Vice President of Strategy at Forte Animal Health, Inc. From March 2020 to December 2020, Mr. Wilson was the Director of Business Intelligence and Strategy at Statera Biopharma Inc. (Nasdaq: STAB), and from December 2020 to June 2022 was its Vice President of Business Strategy and Intelligence. Since January 1998, Mr. Wilson has also been the President of Pixelheads, Inc. (formerly, Webfoot Marketing, Inc.). From January 2012 to March 2020, Mr. Wilson was Senior Marketing Consultant and Content Developer of the Company. Mr. Wilson holds an Associate of Arts from Palm Beach Community College and attended the University of Central Florida for Technical Writing.


There are no arrangements or understandings between Mr. Wilson and any other persons pursuant to which he was selected as President. Mr. Wilson is married to Kelly O. Wilson, the Chief Executive Officer, and Chief Operating Officer of the Company. Mr. Wilson is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K.